Study Summary:
An 8-week, Placebo-controlled, Double-blind, Randomized, Fixed-dose Efficacy and Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia
Qualified Participants Must:
• Must be between 12 and 18 years of age
•
Have schizophrenia, diagnosed, confirmed and reconfirmed by board-eligible or board certified psychiatrists with at least two years of specialization in pediatric/adolescent psychiatric medicine
•
Qualified Participants May Receive:
Study medication and all study related visits at no cost. In addition, possible compensation for each completed visit.